A biotechnology company has used AI to design gene-editing tools that have been successfully used to edit DNA in human cells. These AI-designed molecules will be freely available under the OpenCRISPR initiative, potentially revolutionizing gene editing and its applications in treating genetic diseases and aging research. While the technology holds immense promise, ethical considerations and rigorous testing through clinical trials are crucial as it moves closer to clinical applications.
read more